Skip to main content
Premium Trial:

Request an Annual Quote

Fitch Affirms Bio-Rad Ratings At BBB-

NEW YORK (GenomeWeb) – Fitch Ratings today affirmed the ratings of Bio-Rad Laboratories, including the issuer default rating, at BBB- .

Additionally, Fitch assigned a BBB- rating to the firm's senior unsecured bank notes and its senior unsecured bank facility and said that Bio-Rad's rating outlook is stable.

The ratings apply to approximately $437 million of debt at Sept. 30, 2014.

Bio-Rad recently settled bribery investigations by the US Department of Justice and the US Securities and Exchange Commission pertaining to past violations of the Foreign Corrupt Practices Act. In Q4 2014 the company will pay $55 million in penalties comprising a $14.4 million penalty under a non-prosecution agreement and a $40.7 million civil settlement. The full cost of litigation is easily manageable given Bio-Rad's solid liquidity, Fitch said in a statement.

Fitch also noted that it sees sustained revenue growth for Bio-Rad in the 2 to 3 percent range and overall sales increases from clinical diagnostics in the 2 to 3 percent range over the ratings horizon.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.